11 research outputs found
Forging New Library Connections Between Vermont and Peru
Researchers at the University of Vermont in Burlington, Vermont (UVM) and the Pontifical Catholic University of Peru in Lima, Peru (PUCP) have built extended collaborative relationships based on an umbrella affiliation agreement between the two institutions. Originally centered on health technology and instrumentation, the relationship soon expanded to include partnerships in science and engineering, public administration and, most recently, in library collaboration. In September 2015, three of us from the UVM Libraries travelled to PUCP for a week to strengthen library connections between our universities. In order to understand the PUCP research context and the role of librarians at the university, people spent several intensive days collaborating with librarians and staff. At the end of the week, we had forged new connections with our colleagues in Peru, and had learned about both the similarities and differences in issues that the as academic librarians face in our daily work
Recurrent Prostate Cancer Diagnostics with 18F-PSMA-1007 PET/CT: A Systematic Review of the Current State
Funding Information: This research was funded by Latvian Council of Science, grant number: lzp-2019/1-0056 “Impact of Targeted Molecular Imaging with 18F-PSMA-1007 and 68Ga-PSMA-11 PET/CT in Multimodal Evaluation of Recurrent Prostate Cancer”. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101008571 (PRISMAP). This document reflects only the view of the author(s). The funding agenc(y/ies) is/are not responsible for any use that may be made of the information it contains. Publisher Copyright: © 2022 by the authors.BACKGROUND: Early diagnosis of recurrent prostate cancer is a cornerstone for further adequate therapy planning. Therefore, clinical practice and research still focuses on diagnostic tools that can detect prostate cancer in early recurrence when it is undetectable in conventional diagnostic imaging. 18F-PSMA-1007 PET/CT is a novel method to evaluate patients with biochemical recurrent PCa. The aim of this review was to evaluate the role of 18F-PSMA-1007 PET/CT in prostate cancer local recurrence, lymph node metastases and bone metastases detection. METHODS: Original studies, reviews and five meta-analyses were included in this article. A total of 70 studies were retrieved, 31 were included in the study. RESULTS: All patients described in the studies underwent 18F-PSMA-1007 PET/CT. The administered 18F-PSMA-1007 individual dose ranged from 159 ± 31 MBq to 363.93 ± 69.40 MBq. Results showed that 18F-PSMA-1007 PET/CT demonstrates a good detection rate in recurrent prostate cancer. CONCLUSIONS: 18F-PSMA-1007 PET/CT appears to achieve reliable performance in detecting recurrent prostate cancer. The high detection rate of 18F-PSMA-1007 PET/CT in recurrent prostate cancer was confirmed, especially in local recurrence and small lymph nodes with non-specific characteristics on conventional diagnostic imaging methods. However, several authors emphasize some limitations for this tracer-for example, non-specific uptake in bone lesions that can mimic bone metastases.publishersversionPeer reviewe
User Instruction Issues for Databases in the Humanities
published or submitted for publicatio
Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study
Background Gaps in the diagnostic capacity and heterogeneity of national surveillance and reporting standards in Europe make it difficult to contain carbapenemase-producing Enterobacteriaceae. We report the development of a consistent sampling framework and the results of the first structured survey on the occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in European hospitals. Methods National expert laboratories recruited hospitals with diagnostic capacities, who collected the first ten carbapenem non-susceptible clinical isolates of K pneumoniae or E coli and ten susceptible same-species comparator isolates and pertinent patient and hospital information. Isolates and data were relayed back to national expert laboratories, which made laboratory-substantiated information available for central analysis. Findings Between Nov 1, 2013, and April 30, 2014, 455 sentinel hospitals in 36 countries submitted 2703 clinical isolates (2301 [85%] Kpneurnoniae and 402 (15%) Ecoli). 850 (37%) of 2301 Kpneumoniae samples and 77 (19%) of 402 Ecoli samples were carbapenemase (KPC, NDM, OXA-48-like, or VIM) producers. The ratio of K pneumoniae to E coli was 11:1.1.3 patients per 10000 hospital admissions had positive clinical specimens. Prevalence differed greatly, with the highest rates in Mediterranean and Balkan countries. Carbapenemase-producing K pneumoniae isolates showed high resistance to last-line antibiotics. Interpretation This initiative shows an encouraging commitment by all participants, and suggests that challenges in the establishment of a continent-wide enhanced sentinel surveillance for carbapenemase-producing Entero-bacteriaeceae can be overcome. Strengthening infection control efforts in hospitals is crucial for controlling spread through local and national health care networks
Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread
Public health interventions to control the current epidemic of
carbapenem-resistant Klebsiella pneumoniae rely on a comprehensive
understanding of its emergence and spread over a wide range of
geographical scales. We analysed the genome sequences and
epidemiological data of >1,700 K. pneumoniae samples isolated from
patients in 244 hospitals in 32 countries during the European Survey of
Carbapenemase-Producing Enterobacteriaceae. We demonstrate that
carbapenemase acquisition is the main cause of carbapenem resistance and
that it occurred across diverse phylogenetic backgrounds. However, 477
of 682 (69.9%) carbapenemase-positive isolates are concentrated in four
clonal lineages, sequence types 11,15,101, 258/512 and their
derivatives. Combined analysis of the genetic and geographic distances
between isolates with different beta-lactam resistance determinants
suggests that the propensity of K. pneumoniae to spread in hospital
environments correlates with the degree of resistance and that
carbapenemase-positive isolates have the highest transmissibility.
Indeed, we found that over half of the hospitals that contributed
carbapenemase-positive isolates probably experienced within-hospital
transmission, and interhospital spread is far more frequent within,
rather than between, countries. Finally, we propose a value of 21 for
the number of single nucleotide polymorphisms that optimizes the
discrimination of hospital clusters and detail the international spread
of the successful epidemic lineage, ST258/512
Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study
Background Gaps in the diagnostic capacity and heterogeneity of national
surveillance and reporting standards in Europe make it difficult to
contain carbapenemase-producing Enterobacteriaceae. We report the
development of a consistent sampling framework and the results of the
first structured survey on the occurrence of carbapenemase-producing
Klebsiella pneumoniae and Escherichia coli in European hospitals.
Methods National expert laboratories recruited hospitals with diagnostic
capacities, who collected the first ten carbapenem non-susceptible
clinical isolates of K pneumoniae or E coli and ten susceptible
same-species comparator isolates and pertinent patient and hospital
information. Isolates and data were relayed back to national expert
laboratories, which made laboratory-substantiated information available
for central analysis.
Findings Between Nov 1, 2013, and April 30, 2014, 455 sentinel hospitals
in 36 countries submitted 2703 clinical isolates (2301 [85%]
Kpneurnoniae and 402 (15%) Ecoli). 850 (37%) of 2301 Kpneumoniae
samples and 77 (19%) of 402 Ecoli samples were carbapenemase (KPC, NDM,
OXA-48-like, or VIM) producers. The ratio of K pneumoniae to E coli was
11:1.1.3 patients per 10000 hospital admissions had positive clinical
specimens. Prevalence differed greatly, with the highest rates in
Mediterranean and Balkan countries. Carbapenemase-producing K pneumoniae
isolates showed high resistance to last-line antibiotics.
Interpretation This initiative shows an encouraging commitment by all
participants, and suggests that challenges in the establishment of a
continent-wide enhanced sentinel surveillance for
carbapenemase-producing Entero-bacteriaeceae can be overcome.
Strengthening infection control efforts in hospitals is crucial for
controlling spread through local and national health care networks